Disclosed are formulations of pirfenidone or pyridone analog compounds for nebulised inhlalation adminsitration. Also disclosed is the use of such formulations for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system.
